Pharmacology NR566 final
Correct 100%
For treatment of existing osteoporosis, the dose of alendronate - ANSWER 10 mg/day or 70
mg/week
Initial dosage for bone less prevention alendronate and risedronate - ANSWER 5 mg/day or 35
mg/week
Testosterone replacement therapy - ANSWER Erythrocytosis is a risk; Hgb and Hct levels checked,
expect increase first 6 mths, unless Hgb level higher than 17.5 g/dL, Hct higher than 54%, or both
suggests overtreatment or occasionally abuse. IM happens more than transdermal. If the Hct is
greater than 54%, therapy is stopped until the Hct decreases to a safe level. The patient should also
be evaluated for hypoxia and sleep apnea. Restarting therapy at a reduced dose usually solves
problems.
For treatment of existing osteoporosis, the dose of risedronate - ANSWER 75 mg for 2 consecutive
days or 150 mg once a month
Alendronate (Fosamax) - ANSWER Therapy with 10 mg daily can increase bone density by up to 10%
after 3 years and can decrease vertebral and hip fractures by 50%
Testosterone replacement therapy - ANSWER risk of prostate cancer
Adults with vitamin B12 deficiency that is not pernicious anemia - ANSWER 1,000 mcg of oral
cobalamin are given until normal B12 levels are achieved—usually 6 to 12 weeks. In seriously ill
patients, both vitamin B12 and folic acid may need to be administered.
Who cannot get TRT - ANSWER breast cancer in a male patient, prostrate cancer, polycythemia vera,
increased calcium in the blood from cancer, diabetes, high cholesterol, overweight and high blood
pressure
BC contraindications - ANSWER Age >40 yr or Smoker <35 yr
, BMI >30 due to increased VTE risk
HTN or hyperlipidemia
First-degree relative with DVT/PE
Major surgery without prolonged immobilization
Superficial thrombophlebitis
SLE on immunosuppressive therapy or with severe thrombocytopenia
Rheumatoid arthritis Sickle cell disease
BC contraindications - ANSWER Valvular heart disease, uncomplicated
Migraine without neurological aura, age <35 yr
Unexplained vaginal bleeding, suspicious for serious underlying condition
Cervical intraepithelial neoplasia
Cervical cancer, awaiting treatment
Undiagnosed breast mass
BC contraindications - ANSWER Diabetes, insulin dependent or non-insulin-dependent, without
vascular disease
Asymptomatic gallbladder disease or postcholecystectomy
Benign focal nodular hyperplasia of the liver
Hx of cholestasis in pregnancy
Ulcerative colitis or Crohn's disease
Postpartum & breastfeeding
ethinyl estradiol/norgestimate contraindications - ANSWER Current or prior history of an estrogen-
dependent cancer
Pregnancy
Undiagnosed dysfunctional uterine bleeding
DVT
Arterial thromboemboli within the prior year
Clotting disorders
Severe hepatic disease.
Correct 100%
For treatment of existing osteoporosis, the dose of alendronate - ANSWER 10 mg/day or 70
mg/week
Initial dosage for bone less prevention alendronate and risedronate - ANSWER 5 mg/day or 35
mg/week
Testosterone replacement therapy - ANSWER Erythrocytosis is a risk; Hgb and Hct levels checked,
expect increase first 6 mths, unless Hgb level higher than 17.5 g/dL, Hct higher than 54%, or both
suggests overtreatment or occasionally abuse. IM happens more than transdermal. If the Hct is
greater than 54%, therapy is stopped until the Hct decreases to a safe level. The patient should also
be evaluated for hypoxia and sleep apnea. Restarting therapy at a reduced dose usually solves
problems.
For treatment of existing osteoporosis, the dose of risedronate - ANSWER 75 mg for 2 consecutive
days or 150 mg once a month
Alendronate (Fosamax) - ANSWER Therapy with 10 mg daily can increase bone density by up to 10%
after 3 years and can decrease vertebral and hip fractures by 50%
Testosterone replacement therapy - ANSWER risk of prostate cancer
Adults with vitamin B12 deficiency that is not pernicious anemia - ANSWER 1,000 mcg of oral
cobalamin are given until normal B12 levels are achieved—usually 6 to 12 weeks. In seriously ill
patients, both vitamin B12 and folic acid may need to be administered.
Who cannot get TRT - ANSWER breast cancer in a male patient, prostrate cancer, polycythemia vera,
increased calcium in the blood from cancer, diabetes, high cholesterol, overweight and high blood
pressure
BC contraindications - ANSWER Age >40 yr or Smoker <35 yr
, BMI >30 due to increased VTE risk
HTN or hyperlipidemia
First-degree relative with DVT/PE
Major surgery without prolonged immobilization
Superficial thrombophlebitis
SLE on immunosuppressive therapy or with severe thrombocytopenia
Rheumatoid arthritis Sickle cell disease
BC contraindications - ANSWER Valvular heart disease, uncomplicated
Migraine without neurological aura, age <35 yr
Unexplained vaginal bleeding, suspicious for serious underlying condition
Cervical intraepithelial neoplasia
Cervical cancer, awaiting treatment
Undiagnosed breast mass
BC contraindications - ANSWER Diabetes, insulin dependent or non-insulin-dependent, without
vascular disease
Asymptomatic gallbladder disease or postcholecystectomy
Benign focal nodular hyperplasia of the liver
Hx of cholestasis in pregnancy
Ulcerative colitis or Crohn's disease
Postpartum & breastfeeding
ethinyl estradiol/norgestimate contraindications - ANSWER Current or prior history of an estrogen-
dependent cancer
Pregnancy
Undiagnosed dysfunctional uterine bleeding
DVT
Arterial thromboemboli within the prior year
Clotting disorders
Severe hepatic disease.
